Onconetix, Inc. (NASDAQ:ONCO) Short Interest Update

Onconetix, Inc. (NASDAQ:ONCO) saw a significant growth in short interest in February. As of February 13th, there was short interest totaling 158,751 shares, a growth of 48.1% from the January 29th total of 107,197 shares. Approximately 10.3% of the shares of the stock are sold short. Based on an average daily trading volume, of 715,859 shares, the short-interest ratio is presently 0.2 days. Based on an average daily trading volume, of 715,859 shares, the short-interest ratio is presently 0.2 days. Approximately 10.3% of the shares of the stock are sold short.

Institutional Investors Weigh In On Onconetix

A hedge fund recently bought a new stake in Onconetix stock. Citadel Advisors LLC acquired a new stake in Onconetix, Inc. (NASDAQ:ONCO) in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 15,633 shares of the company’s stock, valued at approximately $49,000. Citadel Advisors LLC owned 1.00% of Onconetix as of its most recent SEC filing. Institutional investors own 23.89% of the company’s stock.

Onconetix Trading Down 2.8%

Shares of NASDAQ:ONCO traded down $0.02 on Monday, hitting $0.65. The company had a trading volume of 58,584 shares, compared to its average volume of 452,894. Onconetix has a 52-week low of $0.62 and a 52-week high of $23.38. The business has a 50 day moving average of $1.33 and a 200 day moving average of $2.36. The company has a market cap of $1.01 million, a PE ratio of 0.06 and a beta of 3.52.

About Onconetix

Onconetix, Inc, a biotechnology company, focuses on the research, development, and commercialization of solutions for men's health and oncology. It offers Entadfi, an FDA-approved, once daily pill that combines finasteride and tadalafil for the treatment of benign prostatic hyperplasia; and Proclarix, an in vitro protein-based blood diagnostic test for prostate cancer. The company was formerly known as Blue Water Biotech, Inc and changed its name to Onconetix, Inc in December 2023. Onconetix, Inc was incorporated in 2018 and is headquartered in Cincinnati, Ohio.